Biotech Companies; Recent Milestones and Potential Upside

New York, NY -- December 22, 2020 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new research.

SAMM SOLUTIONS, INC. (DBA BTS Research) has been engaged by Enzolytics, Inc. (OTCPINK: ENZC) to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. Harry Zhabilov, CSO stated " This is a big step for our organization, and we hope to be able to use most if not all of the information from our already successful Clinical Trials in Bulgaria to speed our attempt to meet the requirements in the US for approval."

The long phase 3 clinical trial conducted by Northwest Biotherapeutics, Inc. (OTCQB: NWBO) to evaluate its one and only immunotherapy candidate, DCVax-L, as a treatment for glioblastoma, concluded in October. Neither the Company nor any party other than the independent statisticians will have access to any unblinded data from the clinical trial at this stage.
"We are excited to be so close to the finish line now, after such a long road" commented Linda Powers, the Company's CEO. "We are hopeful that DCVax®-L can become an important new treatment option for patients who urgently need more and better treatments for Glioblastoma brain cancer."

New under the radar low float biotech in the cardio space, free access READ MORE
Copy and paste to browser may be required https://tradersnewssource.com/dynamic-biotech-coverage/

Vyrologix™, being developed by CytoDyn Inc. (OTCQB: CYDY) reached full enrollment in its Phase 3 registrational trial for patients with severe-to-critical COVID-19. The 390-patient data will be analyzed in approximately 28 days, with expected results to be announced shortly thereafter. CytooDyn’s Phase 2b/3 trial to evaluate the efficacy and safety of Vyrologix™, for patients with severe-to-critical COVID-19 indications is a two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study.
CytoDyn completed enrollment of 390 patients in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population and expects to release results in mid-January 2021.

Innovation Pharmaceuticals Inc. (OTCQB: IPIX) is developing Brilacidin, a Host Defense Protein (HDP) mimetic representing a new class of drug with antiviral, anti-inflammatory, and anti-bacterial properties.
This week, the FDA has approved the Company’s Investigational New Drug (IND) application to proceed with initiation of a Phase 2 clinical trial of Brilacidin in hospitalized patients with COVID-19. With its unique HDP mimetic properties, Brilacidin has potential to exert antiviral activity across SARS-CoV-2 variants. The sudden emergence of highly contagious new variants of the coronavirus illuminates the urgent need for drugs, like Brilacidin, with a different mechanism of action from current antivirals to get this resilient virus under control.

Low float biotech with huge potential in the cardio space trading on the OTCQB READ MORE
Copy and paste to browser may be required https://tradersnewssource.com/dynamic-biotech-coverage/

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Sponsored content, compensation if any is listed in our disclosures under any article or report that mentions a ticker symbol that we have received compensation to advertise.

PRESS RELEASE PROCEDURES

TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source